Tesla disbands Dojo supercomputer team, Bloomberg News reports-February 2024-www.financetom.com

Tesla disbands Dojo supercomputer team, Bloomberg News reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Tesla disbands Dojo supercomputer team, Bloomberg News reports

Aug 7, 2025 2:48 PM

Aug 7 (Reuters) - Tesla is disbanding its Dojo

supercomputer team and its leader, Peter Bannon, will depart the

company, Bloomberg News reported on Thursday, citing people

familiar with the matter.

Reuters could not immediately verify the report.

Previous page： --Tesla Shares Gets Price Target Cut From UBS; Shares Drop over 12% Next page： BRIEF-Westgate Energy Announces Agreement To Acquire Significant Mannville Stack Land Position & US$25 Mln Loan

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--Tesla Shares Gets Price Target Cut From UBS; Shares Drop over 12%

Mar 10, 2025

01:30 PM EDT, 03/10/2025 (MT Newswires) -- Price: 230.40, Change: -32.28, Percent Change: -12.29 ...

BRIEF-Westgate Energy Announces Agreement To Acquire Significant Mannville Stack Land Position & US$25 Mln Loan

Mar 10, 2025

March 10 (Reuters) - Westgate Energy Inc: * WESTGATE ENERGY ANNOUNCES AGREEMENT TO ACQUIRE SIGNIFICANT MANNVILLE STACK LAND POSITION AND A US$25 MILLION LOAN * WESTGATE ENERGY INC - ANNOUNCES $7 MILLION ACQUISITION OF MANNVILLE STACK ASSETS Source text: Further company coverage: ;)) ...

RBC on Oncolytics's Phase 2 Breast Cancer Trial

Mar 10, 2025

01:33 PM EDT, 03/10/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) is planning to enroll ~180 HR+/HER2- mBC patients in a large Phase 2 clinical trial that the company anticipates will support an accelerated approval of pelareorep in breast cancer. Management anticipates that it can generate the primary endpoint (PFS) within two years following the start of patient enrollment,...

Tevogen Bio Files New US Patent for T Cell Vaccine Under Development

Mar 10, 2025

01:18 PM EDT, 03/10/2025 (MT Newswires) -- Tevogen Bio ( TVGN ) said Monday it filed a new patent with the US Patent and Trademark Office for its T cell vaccine that is currently under development. The company said the vaccine's design aims to use its Tevogen.AI-powered PredicTcell technology to identify peptides that stimulate a T cell response, unlike vaccines...